GSK plc (LON: GSK)
London
· Delayed Price · Currency is GBP · Price in GBX 1,358.50
+4.50 (0.33%)
Jan 21, 2025, 6:35 PM BST
GSK plc Revenue
GSK plc had revenue of 8.01B GBP in the quarter ending September 30, 2024, a decrease of -1.66%. This brings the company's revenue in the last twelve months to 31.31B, up 5.59% year-over-year. In the year 2023, GSK plc had annual revenue of 30.33B with 3.42% growth.
Revenue (ttm)
31.31B
Revenue Growth
+5.59%
P/S Ratio
1.77
Revenue / Employee
445.95K
Employees
70,212
Market Cap
55.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
| Indivior | 881.89M |
GSK plc News
- 9 hours ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 10 hours ago - Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer - Benzinga
- 13 hours ago - GSK gets expanded EU approval for Jemperli in endometrial cancer - Seeking Alpha
- 1 day ago - Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84% - Business Upturn
- 2 days ago - Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal - Seeking Alpha
- 6 days ago - GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference - Benzinga
- 7 days ago - Hallucinations in AI: How GSK is addressing a critical problem in drug development - VentureBeat
- 7 days ago - Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals - CNBC